Frontiers of Efficiency: Doing More With Less In Healthcare

Stretched government budgets, especially in Europe, mean that spending is under acute pressure. At the same time, healthcare costs are increasing due to ageing populations and expensive new treatments. The World Health Organisation calculates global health spending at US$8trn, between 10% and 11% of global GDP.

Policymakers must rethink their approaches to tackling stroke

In order to meet global stroke-reduction targets, policymakers must rethink their approaches. One of the key areas identified in a recent EIU report on the global stroke burden is the need to improve education around the risk factors for stroke. New technologies to monitor risk factors and better management of existing medical conditions could help to prevent stroke. Boosting primary healthcare is another vital area for improvement. Finally, establishing clearly defined care pathways from stroke prevention to rehabilitation is crucial.

Frontiers of efficiency: Doing More With Less In Healthcare

Even as government budgets shrink, medical costs continue to rise due to ageing populations and expensive new treatments. The World Health Organisation calculates global health spending at US$8trn, between 10% and 11% of global GDP. Kaveh Safavi, global head of healthcare at consultancy Accenture, estimates that healthcare spending increases 1-3% faster than the rate of economic growth. Governments know they must contain healthcare costs. This report looks at examples of successful initiatives to control healthcare costs while maintaining or improving medical outcomes.

Modernising the Serbian health system

Download the Serbian translation below >>

Modernising the Serbian health system: The need for a reliable decision-making compass

Download the Serbia case study below >>

 

Download the Serbian translation below >>

 

Modernising health systems in the Balkans: Uneven progress

The changing biopharma risk equation

Pharmaceutical companies are in an expansive mode. With rapid advances being made in the development of new therapies, including stem-cell derived therapies and gene therapies, and a growing cohort of potential customers in the burgeoning middle classes of emerging markets, expansion into both new product categories and geographic regions is a priority for most companies.

The changing biopharma risk equation

Pharmaceutical companies are in an expansive mode. With rapid advances being made in the development of new therapies, including stem-cell derived therapies and gene therapies, and a growing cohort of potential customers in the burgeoning middle classes of emerging markets, expansion into both new product categories and geographic regions is a priority for most companies.

The changing biopharma risk equation

However, this class of product—ranging from well-established large-molecule drugs to truly novel therapies—poses major challenges because of their scientific complexity and sophisticated development requirements. Furthermore, expanding the drug pipeline isn’t the only growth strategy most companies are pursuing: They are also planning to expand geographically and expect to face various risks doing so, including unfamiliar regulatory environments, shifts in pricing and customers’ ability to pay.

How mobility impacts the performance of healthcare providers

Sponsored By

Enjoy in-depth insights and expert analysis - subscribe to our Perspectives newsletter, delivered every week